Benefit in upgRading Of duretics with ADministration of loW dose tolvAptan therapY for chronic heart failure in Southern Tohoku reseArch institute for neuRoscience

Benefit in upgRading Of duretics with ADministration of loW dose tolvAptan therapY for chronic heart failure in Southern Tohoku reseArch institute for neuRoscience - Broadway-STAR study

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000030758

Enrollment

100

Registered

2018-01-19

Start date

2018-01-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

heart failure

Interventions

reduction of loop diuretic and administration of low dose TLV(2mg/day) sustained administration of loop diuretic

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)patient of peroral administration of loop diuretic 2)eGFR>30 mL/min/1.73m2 3) more than 20 years old 4) patient of hospitalization 5) Patient with consent ability

Exclusion criteria

Exclusion criteria: 1)Intravenous injection and mechanical support 2)history of hypersensitivity of TLV 3)anuria 4)difficulty of drinking water 5)hypernatremia 6)pregnancy 7)oral administration of TLV 8)acute coronary syndrome 9)Inappropriate patient

Design outcomes

Primary

Measure	Time frame
The rate of re-hospitalization and changes of renal function during 3 years.	—

Secondary

Measure	Time frame
1)body weight 2)congestion 3)renal function 4)cardiac function 5)event	—

Countries

Japan

Contacts

Public ContactHideyuki Takimura

Tokyo General Hospital Division of Cardiovascular center

hideyuki.takimura@mt.strins.or.jp03-3387-5421

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026